Skip to main content
Premium Trial:

Request an Annual Quote

Real Time Genomics Snares $5M Investment

NEW YORK (GenomeWeb News) – Real Time Genomics today announced a $5 million investment for the expansion of its commercial operations.

Steve Lombardi, CEO of Real Time Genomics, declined to identify who the investor is. The San Bruno, Calif.-based genomics analytics firm said that it comprises cash and the conversion of debt. The funding will be used for sales and marketing and for genomics applications development.

Steve Lombardi, CEO of Real Time Genomics, called the financing an "evolutionary milestone for the company where we begin to establish a strong commercial presence in the market."

The company introduced its platform in February. The first version called RTG Family Caller simultaneously analyzes genomic data from related individuals "within a patented Bayesian algorithmic framework" to identify all classes of variants. The system is designed to be compatible with sequencers from providers including Illumina, Life Technologies' Ion Torrent, and Roche's 454 Life Sciences.

In the past month, Real Time Genomics has forged deals with Knome, the J. Craig Venter Institute, and Omicia.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.